Related Experiment Videos
Biomarkers for malignancy in the columnar-lined esophagus
1Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Gastroenterology Clinics of North America
|October 6, 1997
Summary
Understanding Barrett's esophagus progression to cancer is improving. Genetic and biochemical biomarkers are crucial for diagnosing Barrett's metaplasia and dysplasia, aiding surveillance and treatment.
Area of Science:
- Gastroenterology and Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- The progression from normal esophageal squamous mucosa to esophageal adenocarcinoma involves key stages: Barrett's metaplasia and dysplasia.
- Histological diagnosis of Barrett's-associated dysplasia is critical but presents challenges.
- Advancements in understanding the biological mechanisms are paving the way for improved diagnostic tools.
Purpose of the Study:
- To review conventional and novel biomarkers for Barrett's esophagus.
- To highlight the importance of biomarkers in clinical diagnosis and endoscopic surveillance.
- To discuss the role of biomarkers in monitoring therapeutic interventions for Barrett's esophagus.
Main Methods:
- Review of existing literature on biomarkers in Barrett's esophagus.
- Analysis of conventional histological markers.
- Exploration of emerging genetic and biochemical markers.
Main Results:
- Histological assessment remains the gold standard for dysplasia grading.
- Genetic and biochemical markers show promise for early detection and risk stratification.
- Biomarkers can potentially improve the accuracy of endoscopic surveillance and treatment monitoring.
Conclusions:
- Biomarkers are essential complements to histology for managing Barrett's esophagus.
- Further research into novel biomarkers will enhance clinical decision-making.
- The integration of biomarkers is key to advancing the care of patients with Barrett's esophagus.